Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it
has appointed Robert J. Easton to its Board of Directors. Mr. Easton is
a recognized leader in the life sciences and healthcare industries,
having led strategy development and supervised opportunity assessments
for hundreds of clients across the globe, including large and specialty
pharmaceutical companies, early-stage and publicly traded
biopharmaceutical companies, and diagnostics businesses. Mr. Easton
currently serves as Co-Chairman of Bionest Partners, Inc., a consulting
firm he co-founded that specializes in strategic planning for
pharmaceutical, medical device and diagnostic companies.
“Bob’s analytical skills and deep domain knowledge have made him a
valued advisor to many life sciences companies and other healthcare
organizations. We are pleased to have his perspective on our Board, and
look forward to his guidance as we continue to develop our internal
pipeline and further advance our platform technology through strategic
partnerships,” said Arthur H. Tinkelenberg, Ph.D., President and Chief
Executive Officer of Enumeral.
John J. Rydzewski, Executive Chairman of Enumeral, added, “Bob’s
industry experience and strategic insight, coupled with his service as
an independent director of public life sciences companies, will greatly
benefit Enumeral in achieving our strategic and operational objectives
on behalf of our shareholders.”
“I am very excited to join Enumeral’s Board of Directors and have the
opportunity to work with the company’s management team and the other
Enumeral directors,” said Mr. Easton. “Enumeral is well-positioned to
advance immunotherapy discovery and development through their
proprietary technology platform, and I am eager to help contribute to
the company’s growth as a sustainable, public biotechnology company.”
Prior to co-founding Bionest Partners, from 2007 to 2009 Mr. Easton was
a director and Vice President of Apex Bioventures Acquisition
Corporation, a special purpose acquisition company he co-founded that
focused on the healthcare industry. From 2000 to 2006, Mr. Easton served
as Chairman of Easton Associates, LLC, a consulting firm providing
advisory services in the healthcare industry. From 1996 to 2000, he was
a Managing Director of IBM Healthcare Consulting. Previously, Mr. Easton
founded and served as President of The Wilkerson Group, a consulting
firm focused on the pharmaceuticals and medical products industry, which
was acquired by IBM in 1996. Mr. Easton spent 12 years in various
management roles at Union Carbide and Union Carbide Europe, including in
marketing and engineering in the clinical diagnostics business unit. Mr.
Easton has served since 2002 on the Board of Directors of Cepheid, a
molecular diagnostics company, where he also serves on the Nominating
and Governance Committee. He previously served as a director of
CollaGenex Pharmaceuticals, Inc. from 1994 until the company’s sale in
2008. Mr. Easton currently serves as chairman of the New York
Biotechnology Association, and also serves on the Board of Advisors of
the Global Cardiovascular Innovation Center at the Cleveland Clinic. He
is Chairman of the Board of Directors of Gilda’s Club of New York, which
provides social and emotional support to people living with cancer. Mr.
Easton holds B.S. and B.A. degrees in chemical engineering from Rice
University, and an M.B.A. from Harvard University.
Mr. Easton replaces Daniel B. Wolfe, Ph.D., who has stepped down after
serving on the Enumeral board since 2009. Mr. Wolfe was the
representative of Harris & Harris Group, Inc., a venture capital firm
dedicated to building transformative companies from disruptive science,
and was instrumental in founding Enumeral based on technology licensed
from the Massachusetts Institute of Technology.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents,
Enumeral’s researchers apply a proprietary immune profiling technology
platform that measures functioning of the human immune system at the
level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Such statements reflect current beliefs of Enumeral Biomedical
Holdings, Inc. (“Enumeral”) with respect to future events and involve
known and unknown risks, uncertainties, and other factors affecting
operations, market growth, Enumeral’s stock price, services, products
and licenses. No assurances can be given regarding the achievement of
future results, and although Enumeral believes that the expectations
reflected in these forward-looking statements are based on reasonable
assumptions, actual results may differ from the assumptions underlying
the statements that have been made regarding anticipated events. Factors
that may cause actual results, performance or achievements, or industry
results to differ materially from those contemplated by such
forward-looking statements include, among others, the risks that (a)
Enumeral’s expectations regarding market acceptance of the Company’s
business in general and the Company’s ability to penetrate the antibody
discovery and development fields in particular, as well as the timing of
such acceptance, (b) Enumeral’s ability to attract and retain management
with experience in biotechnology and antibody discovery and similar
emerging technologies, (c) the scope, validity and enforceability of
Enumeral’s and third party intellectual property rights, (d) Enumeral’s
ability to raise capital when needed and on acceptable terms and
conditions, (e) Enumeral’s ability to comply with governmental
regulation, (f) the intensity of competition, (g) changes in the
political and regulatory environment and in business and fiscal
conditions in the United States and overseas and (h) general economic
conditions.
More detailed information about Enumeral and risk factors that may
affect the realization of forward-looking statements, including
forward-looking statements in this press release, is set forth in
Enumeral’s filings with the Securities and Exchange Commission. Enumeral
urges investors and security holders to read those documents free of
charge at the Commission’s website at http://www.sec.gov.
Forward-looking statements speak only as to the date they are made, and
except for any obligation under the U.S. federal securities laws,
Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150730006600/en/
Copyright Business Wire 2015